Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4589010 | 0.99 | PPARG (0.49) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| SCHEMBL4589148 | 0.86 | SIGMAR1 (0.48) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| Oxalic Acid SCHEMBL7381576 | 0.86 | PPARG (0.57) | PPARGPPARAHTR7SIGMAR1S1PR5 | |
| SCHEMBL4588594 | 0.86 | PPARG (0.55) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| SCHEMBL4589087 | 0.86 | PPARG (0.50) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| SCHEMBL4589091 | 0.85 | PPARG (0.47) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| SCHEMBL4588826 | 0.85 | SIGMAR1 (0.47) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| SCHEMBL4587710 | 0.85 | SIGMAR1 (0.52) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| Hydrochloric Acid SCHEMBL4588524 | 0.85 | SIGMAR1 (0.47) | PPARGPPARAHTR7SIGMAR1KMT2A | |
| SCHEMBL4587606 | 0.85 | PPARG (0.53) | PPARGPPARAHTR7SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2004-06-24 | — | — | US | claimed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| EP-0950053-B1 | NEW DERIVATIVES OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI SYNTHELABO (FR) | 2003-06-11 | — | — | EP | claimed |
| US-20020058672-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | BARONI MARCO (IT) | 2002-05-16 | — | — | US | claimed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-7297799-B2 | Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-03-08 | — | — | US | disclosed |
| US-7151107-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2006-12-19 | — | — | US | disclosed |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | disclosed |
| US-6936621-B2 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | SANOFI-AVENTIS (FR) | 2005-08-30 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| US-6342505-B1 | inhibiting apoptosis using xaliproden hydrochloride, or other tetrahydropyridine derivatives | SANOFI-SYNTHELABO (FR) | 2002-01-29 | — | — | US | disclosed |
| EP-1017385-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0979079-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 2000-02-16 | — | — | EP | disclosed |
| EP-0950053-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998053821-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 | SANOFI-SYNTHELABO (FR) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998048802-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998028274-A1 | USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS | SANOFI (FR) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058672-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, KCNJ2, CACNA1B | PPARG 3986/4885PPARA 3549/4885HTR7 434/4885 |
| US-20040122032-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, KCNJ2, CACNA1B | PPARG 3986/4885PPARA 3549/4885HTR7 434/4885 |
| US-20070054931-A1 | PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF | BDNF, KCNH1, GABRA6 | PPARG 3161/4885PPARA 2326/4885HTR7 328/4885 |
| US-20050222187-A1 | Use of benzoylalkyl-1,2,3,6-tetrahydropyridines | KCNH1, ATP6V1B2, KCNJ6 | PPARG 3634/4885PPARA 3022/4885HTR7 282/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PPARG 3146/4885PPARA 2134/4885HTR7 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.